Trial Profile

A phase 3 trial of VT3989 in patients with mesothelioma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VT 3989 (Primary)
Indications Mesothelioma
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Vivace Therapeutics

Most Recent Events

17 Mar 2025 New trial record
12 Mar 2025 According to a Vivace Therapeutics media release, company intends to discuss its plans with the United States Food and Drug Administration (FDA) later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com